Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
64.7 CHF | +3.69% | -7.64% | -12.34% |
May. 23 | Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney... | |
May. 22 | DOCMORRIS : Gets a Buy rating from Baader Bank | ZD |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.34% | 852M | B- | ||
-31.33% | 11.31B | B | ||
+15.73% | 6.47B | C | ||
-30.66% | 6.32B | B | ||
-8.33% | 6.09B | C+ | ||
+74.00% | 4.95B | C | ||
-1.61% | 4.67B | D- | ||
-6.00% | 3.95B | B | ||
-14.62% | 3.34B | C- | ||
-12.02% | 2.92B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ROSE Stock
- Ratings DocMorris AG